e-Edition
Obituaries
In Loving Memory
Magazines
Subscribe
Login to Comment
Register
jobs
Menu
Home
News
Sports
Business
Entertainment
Classifieds
Life
Commentary
Contact
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Novo Nordisk A/S Common Stock
(NY:
NVO
)
38.52
+1.87 (+5.09%)
Streaming Delayed Price
Updated: 3:53 PM EST, Mar 4, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
24,323,895
Open
37.63
Bid (Size)
38.52 (4,100)
Ask (Size)
38.53 (1,500)
Prev. Close
36.66
Today's Range
37.29 - 38.58
52wk Range
35.85 - 91.90
Shares Outstanding
N/A
Dividend Yield
3.03%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
The Compounding Cliff: Hims & Hers Faces Reckoning as FDA and Big Pharma Close GLP-1 Loopholes
Today 10:15 EST
NEW YORK — The era of easy access to compounded weight-loss "knockoffs" is rapidly drawing to a close, leaving the telehealth industry’s once-shining star, Hims & Hers Health, Inc. (NYSE: HIMS), in a...
Via
MarketMinute
Topics
Economy
Intellectual Property
Lawsuit
Novo Nordisk’s Brief Rebound Fizzles: Apple-Style Justin Long Ozempic Ad Draws FDA Warning Again
↗
Today 1:21 EST
The notice comes weeks after a similar warning over Wegovy advertising, as the FDA ramps up scrutiny of marketing tied to GLP-1 drugs.
Via
Stocktwits
Performance
YTD
-26.5%
-26.5%
1 Month
-34.6%
-34.6%
3 Month
-18.8%
-18.8%
6 Month
-31.7%
-31.7%
1 Year
-56.9%
-56.9%
More News
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S - NVO
March 03, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead?
↗
March 03, 2026
Via
The Motley Fool
Topics
Intellectual Property
Unexpected Stock Picks and Looking to the Future
↗
March 02, 2026
Via
The Motley Fool
Why I'm Not Worried About Novo Nordisk Stock
↗
March 02, 2026
Via
The Motley Fool
Topics
Intellectual Property
MarketBeat Week in Review – 02/23 - 02/27
↗
February 28, 2026
Via
MarketBeat
The Great Divergence: AI Supremacy Masks a Hidden Bear Market in Healthcare and Industrials
February 27, 2026
Via
MarketMinute
Topics
Artificial Intelligence
Bonds
Economy
The Lilly Era: How Eli Lilly Transformed into a Trillion-Dollar Healthcare Titan
February 27, 2026
Via
MarketMinute
Topics
Artificial Intelligence
ETFs
The Valuation Reset: A Deep-Dive into Novo Nordisk (NVO) in 2026
February 27, 2026
Via
Finterra
Topics
Economy
Intellectual Property
Got $5,000? Hims & Hers Could Be a Direct‑to‑Consumer Health Moonshot in the Making
↗
February 27, 2026
Via
The Motley Fool
Forget Altimmune: This Proven Obesity‑Drug Giant Is the Better Weight‑Loss Play
↗
February 26, 2026
Via
The Motley Fool
Why Shares of Novo Nordisk Stock Sank (Again) This Week
↗
February 26, 2026
Via
The Motley Fool
Viking Therapeutics: The High-Stakes Weight Loss Contender
↗
February 26, 2026
Via
MarketBeat
The Darwinian Transition: AI Monetization and Metabolic Mastery Define the Market’s New Frontier
February 26, 2026
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Hims & Hers at the Crossroads: Navigating the ‘Regulatory Winter’ of 2026
February 26, 2026
Via
Finterra
Topics
Economy
Initial Public Offering
Intellectual Property
Hims & Hers: The Telehealth Growth Story Younger Investors Can't Afford to Ignore
↗
February 26, 2026
Via
The Motley Fool
Stock Market Today, Feb. 25: Novo Nordisk Dips After Announcing $2.1 Billion Partnership With Vivtex for Oral Drug-Delivery Technologies
↗
February 25, 2026
Via
The Motley Fool
Topics
Stocks
Eli Lilly Just Took 2 Major Steps Forward in the Billion-Dollar Obesity Drug Market. Here's What You Need to Know.
↗
February 25, 2026
Via
The Motley Fool
1 Reason Why I'd Hold This Weight‑Loss Drug Leader Through Any Market Crash
↗
February 25, 2026
Via
The Motley Fool
Topics
Economy
NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm
February 25, 2026
From
Schall Law
Via
GlobeNewswire
Novo, Vivtex Ink $2.1 Billion Deal To Develop Oral Medicines For Obesity And Diabetes
↗
February 25, 2026
Via
Stocktwits
Novo Nordisk To Slash GLP-1 Drug Prices By Up To 50% In US Starting 2027
↗
February 25, 2026
Via
Benzinga
Could Novo Nordisk Help Turn $100,000 Into $1 Million in the GLP‑1 Gold Rush?
↗
February 25, 2026
Via
The Motley Fool
Why Eli Lilly Stock Slumped Today
↗
February 24, 2026
Via
The Motley Fool
Frequently Asked Questions
Is Novo Nordisk A/S Common Stock publicly traded?
Yes, Novo Nordisk A/S Common Stock is publicly traded.
What exchange does Novo Nordisk A/S Common Stock trade on?
Novo Nordisk A/S Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Novo Nordisk A/S Common Stock?
The ticker symbol for Novo Nordisk A/S Common Stock is NVO on the New York Stock Exchange
What is the current price of Novo Nordisk A/S Common Stock?
The current price of Novo Nordisk A/S Common Stock is 38.52
When was Novo Nordisk A/S Common Stock last traded?
The last trade of Novo Nordisk A/S Common Stock was at 03/04/26 03:53 PM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
wpDiscuz
Insert